Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis

We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-r...

Descripción completa

Detalles Bibliográficos
Autores principales: Achar, Jay, Hewison, Cathy, Cavalheiro, Ana P., Skrahina, Alena, Cajazeiro, Junia, Nargiza, Parpieva, Herboczek, Krzysztof, Rajabov, Assliddin S., Hughes, Jennifer, Ferlazzo, Gabriella, Seddon, James A., du Cros, Philipp
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Centers for Disease Control and Prevention 2017
Materias:
Dispatch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5621552/
https://www.ncbi.nlm.nih.gov/pubmed/28758889
http://dx.doi.org/10.3201/eid2310.170303
Descripción
Sumario:We describe 27 children and adolescents <18 years of age who received bedaquiline during treatment for multidrug-resistant tuberculosis. We report good treatment responses and no cessation attributable to adverse effects. Bedaquiline could be considered for use with this age group for multidrug-resistant tuberculosis when treatment options are limited.

Ejemplares similares